[go: up one dir, main page]

WO2017220050A3 - Composition pharmaceutique d'azithromycine et son utilisation médicale pour soulager la toux - Google Patents

Composition pharmaceutique d'azithromycine et son utilisation médicale pour soulager la toux Download PDF

Info

Publication number
WO2017220050A3
WO2017220050A3 PCT/CN2017/097788 CN2017097788W WO2017220050A3 WO 2017220050 A3 WO2017220050 A3 WO 2017220050A3 CN 2017097788 W CN2017097788 W CN 2017097788W WO 2017220050 A3 WO2017220050 A3 WO 2017220050A3
Authority
WO
WIPO (PCT)
Prior art keywords
azithromycin
cough
pharmaceutical composition
medical use
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/097788
Other languages
English (en)
Chinese (zh)
Other versions
WO2017220050A2 (fr
Inventor
崔坤峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017220050A2 publication Critical patent/WO2017220050A2/fr
Publication of WO2017220050A3 publication Critical patent/WO2017220050A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A61K36/8884—Arisaema, e.g. Jack in the pulpit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique d'azithromycine et son utilisation médicale pour soulager la toux. La composition pharmaceutique d'azithromycine contient de l'azithromycine et un composé de produit naturel (I) séparé du rhizoma arariématitis séché et ayant une nouvelle structure. Lorsqu'ils sont utilisés individuellement, l'azithromycine et le composé de produit naturel (I) ont un effet anti-inflammatoire et de soulagement de la toux. Lorsqu'ils sont utilisés ensemble, les deux composés améliorent en outre l'effet anti-inflammatoire et de soulagement de la toux, peuvent être développés sous la forme d'un médicament anti-inflammatoire et de soulagement de la toux, et ont des caractéristiques significatives importantes et représentent un progrès notable par rapport à l'état de la technique.
PCT/CN2017/097788 2016-06-23 2017-08-17 Composition pharmaceutique d'azithromycine et son utilisation médicale pour soulager la toux Ceased WO2017220050A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610463311.0 2016-06-23
CN201610463311.0A CN106146601A (zh) 2016-06-23 2016-06-23 阿奇霉素的药物组合物及其止咳的医药用途

Publications (2)

Publication Number Publication Date
WO2017220050A2 WO2017220050A2 (fr) 2017-12-28
WO2017220050A3 true WO2017220050A3 (fr) 2018-02-15

Family

ID=57353752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/097788 Ceased WO2017220050A2 (fr) 2016-06-23 2017-08-17 Composition pharmaceutique d'azithromycine et son utilisation médicale pour soulager la toux

Country Status (2)

Country Link
CN (1) CN106146601A (fr)
WO (1) WO2017220050A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105837449A (zh) * 2016-04-18 2016-08-10 镇江高海生物药业有限公司 一种l-叔亮氨酸的药物组合物及其在生物医药中的应用
CN105884741A (zh) * 2016-04-23 2016-08-24 徐挺 一种富马酸比索洛尔的药物组合物及其医药用途
CN106045835A (zh) * 2016-06-23 2016-10-26 崔坤峰 盐酸苄丝肼的药物组合物及其降血糖的医药用途
CN106146601A (zh) * 2016-06-23 2016-11-23 崔坤峰 阿奇霉素的药物组合物及其止咳的医药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104107358A (zh) * 2014-07-21 2014-10-22 河南科技大学第一附属医院 一种用于止咳化痰的药丸及其制备方法
CN105663138A (zh) * 2016-04-23 2016-06-15 贺玉皓 一种氯硝西泮的药物组合物及其医药用途
CN105837449A (zh) * 2016-04-18 2016-08-10 镇江高海生物药业有限公司 一种l-叔亮氨酸的药物组合物及其在生物医药中的应用
CN105884741A (zh) * 2016-04-23 2016-08-24 徐挺 一种富马酸比索洛尔的药物组合物及其医药用途
CN106146601A (zh) * 2016-06-23 2016-11-23 崔坤峰 阿奇霉素的药物组合物及其止咳的医药用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104107358A (zh) * 2014-07-21 2014-10-22 河南科技大学第一附属医院 一种用于止咳化痰的药丸及其制备方法
CN105837449A (zh) * 2016-04-18 2016-08-10 镇江高海生物药业有限公司 一种l-叔亮氨酸的药物组合物及其在生物医药中的应用
CN105663138A (zh) * 2016-04-23 2016-06-15 贺玉皓 一种氯硝西泮的药物组合物及其医药用途
CN105884741A (zh) * 2016-04-23 2016-08-24 徐挺 一种富马酸比索洛尔的药物组合物及其医药用途
CN106146601A (zh) * 2016-06-23 2016-11-23 崔坤峰 阿奇霉素的药物组合物及其止咳的医药用途

Also Published As

Publication number Publication date
WO2017220050A2 (fr) 2017-12-28
CN106146601A (zh) 2016-11-23

Similar Documents

Publication Publication Date Title
WO2016131067A3 (fr) Compositions pharmaceutiques contenant du méloxicam
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
WO2015151079A3 (fr) Analogues d'auristatine et leur conjugués avec des molécules de liaison cellulaire
WO2018004283A3 (fr) Dérivé du glucagon, conjugué de celui-ci, composition le comprenant et utilisation thérapeutique de celui-ci
CO2022002374A2 (es) Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
WO2015077503A8 (fr) Composés inhibiteurs de l'autotaxine
ZA201902051B (en) Pharmaceutical composition
HK1247856A1 (zh) 羟丙基β-环糊精组合物及方法
EP3569596A4 (fr) Dérivé de 1,2,4-triazine-3-amine, son procédé de préparation et son utilisation en médecine
WO2017220050A3 (fr) Composition pharmaceutique d'azithromycine et son utilisation médicale pour soulager la toux
WO2018200143A3 (fr) Compositions d'extraits de schisandra et méthodes associées
WO2017220042A3 (fr) Composition pharmaceutique d'amrinone et son application dans le traitement de l'hypertension
WO2016056026A3 (fr) Composition synergique pour l'arthrose
EP4342461A3 (fr) Compositions pharmaceutiques et utilisations contre des troubles du stockage lysosomal
WO2017205964A8 (fr) Dérivés aminostéroïdes et leur procédé de production
WO2016040814A3 (fr) Polymères de bisulfure et procédés d'utilisation associés
WO2017220041A3 (fr) Composition pharmaceutique de bézafibrate et son application dans la polyarthrite rhumatoïde
WO2017215678A3 (fr) Composition pharmaceutique de céfaclor et ses effets protecteurs contre les lésions pulmonaires aiguës
WO2017215677A3 (fr) Composition pharmaceutique de carbocistéine et ses effets thérapeutiques sur la leucémie
WO2014165513A3 (fr) Biopolymères d'acide hyaluronique éthylsulfonaté et leurs procédés d'utilisation
DK3888647T3 (da) Ezh1/2-dobbeltinhibitor-holdig farmaceutisk sammensætning, der skal anvendes som kombinationslægemiddel
WO2017215680A3 (fr) Composition pharmaceutique de chlorprothixène et ses effets de protection contre les lésions de reperfusion d'ischémie cérébrale
EP3991723A4 (fr) Composition pharmaceutique à stabilité améliorée comprenant un extrait de produit naturel
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
WO2012168680A8 (fr) Préparation pharmaceutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17814787

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17814787

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 17/07/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17814787

Country of ref document: EP

Kind code of ref document: A2